The Department of Health (DH) today (9 March) endorsed a licensed drug wholesaler, namely Healthcare Division O/B DCH Auriga (Hong Kong) Limited (DCH Auriga), distributor appointed by the holder of certificate of drug registration, Hutchmed (Hong Kong) Limited O/B Hutchmed (Hong Kong) Limited (Hutchmed), to voluntarily recall one registered pharmaceutical product, namely Tazverik Tablets 200mg (Hong Kong Registration number: HK-68216) from the market due to potential safety risks.
The DH received notification from Hutchmed that the overseas manufacturer of the product is recalling the above batches of Tazverik Tablets due to ongoing clinical trial data indicating an increased risk of secondary haematologic malignancies, where the potential risks may outweigh the therapeutic benefits. Therefore, Hutchmed voluntarily recalls the above product from the market.
The above product, containing tazemetostat, is a prescription medicine indicated for the treatment of blood cancer. According to Hutchmed, the above product was imported into Hong Kong and distributed by DCH Auriga and has been supplied to the Hospital Authority, local private hospitals, private doctors and exported to Macau.
Hutchmed has issued letters to Healthcare Professional and Press Statement regarding the product recall.
Hutchmed has also set up a hotline (2121 3846) to answer related enquiries.
So far, the DH has received one adverse reaction report associated with one batch (batch no. 3225173) of the product, but the case was not related to secondary haematologic malignancies. The DH will closely monitor the recall.
Patients who have used the above product should immediately consult their healthcare professionals.
Reposted from HKSAR Government webpage:
https://www.drugoffice.gov.hk/eps/news/showNews/Recall/pharmaceutical_trade/2026-03-09/en/57013.html